SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant market attention as traders bet on a potential short squeeze amid high short interest and heavy institutional buying. The community remains focused on upcoming regulatory catalysts, global manufacturing expansion for its cell therapy platform, and the company's long-term potential to transform oncology treatment.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility as investors weigh a strong growth narrative against persistent stock price pressure near annual lows, fueled by concerns over Alani Nu integration and competitive dynamics. The community is actively debating whether current levels represent an institutional accumulation phase ahead of upcoming earnings or reflect deeper structural headwinds in the energy drink sector.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following the successful closure of a $600 million AAA-rated asset-backed securities transaction, which has bolstered investor confidence in its AI-driven credit underwriting model. The community is currently focused on the stock's potential for a recovery, emphasizing its move toward sustained profitability and the expansion of its institutional partner network despite broader macro-economic and geopolitical headwinds.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to a significant stock price surge following a strong earnings report that topped expectations for both revenue and customer growth. The community is actively discussing the stock's resilience in the software sector, potential long-term benefits from AI infrastructure demands, and the reliability of its observability platform despite broader concerns about software sector valuations.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is currently trending due to a massive disconnect between its strong fundamentals and recent stock price volatility, with investors debating whether the stock is a 'profit machine' or vulnerable to dilution from a shelf offering. The community is sharply divided, with bulls pointing to record-breaking margins and AI-driven growth, while some bears are signaling caution regarding potential SEC investigation risks and the broader software sector's recent underperformance.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending following a surge in trading volume and investor interest sparked by a report highlighting its role as a key supplier for AI infrastructure and optics. The community is actively debating the sustainability of this rally, with discussions centered on potential institutional positioning, the impact of heavy call option activity, and the company's long-term integration into advanced data center technologies.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul and the acquisition of Kezar Life Sciences. The market is actively debating whether these aggressive moves under new management signal an accelerated path toward a potential buyout or a strategic shift in long-term pipeline development.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility driven by ongoing debates over Elevidys clinical efficacy and concerns regarding Roche's decision to initiate a new global Phase 3 trial for the therapy. While the community remains deeply polarizedwith some investors highlighting undervaluation relative to the company's approved portfolio and others raising alarms over regulatory hurdles and potential cash burnsentiment is further pressured by aggressive analyst downgrades and persistent short interest.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is drawing heavy investor attention as the company aggressively pivots to value-focused menus, including new low-cost offerings and specialty drink expansions designed to combat rising operational costs and intense competition. Community sentiment is mixed, with some traders betting on a defensive rotation into the stock as a recession hedge, while others voice concerns regarding menu quality and the effectiveness of current leadership.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending after reporting that its ERNA-101 cell therapy achieved complete tumor clearance and long-term survival in ovarian cancer models, fueling community speculation about its potential as a severely undervalued biotech opportunity. Investors are actively debating the significance of the preclinical animal data and the company's recent reverse split, with some highlighting it as a high-reward clinical candidate while others caution against potential future dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


tip88ecom

Nhà Cái Tip88